Advertisement

Topics

Latest Biotechnology Products NewsRSS

06:46 EDT 25th July 2017 | BioPortfolio

Atterx Biotherapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile. [Report Updated: 20072017] Prices from USD $250

SummaryAtterx Biotherapeutics Inc Atterx formerly ConjuGon Inc, is a biotechnology company that develops anti bacterial products. The company develops and distributes technologies and products to eliminate bacterial infections. It develops and commercializes conjugationbased antibacterial technology. Atterx's products comprise C1205, GP505 and GN4474. The company's C1205 prevents catheterassociate...

Aeglea BioTherapeutics Inc AGLE Pharmaceuticals Healthcare Deals and Alliances Profile. [Report Updated: 20072017] Prices from USD $250

SummaryAeglea BioTherapeutics Inc Aeglea BioTherapeutics, formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company that develops and commercializes engineered human enzymes for the treatment of cancer and rare genetic diseases. The company's product pipeline comprises AEB1102, AEB3103, AEB2109, and AEB4104. It develops engineered human enzymes to target and degrade amino acids in t...

Atara Biotherapeutics Inc ATRA Pharmaceuticals Healthcare Deals and Alliances Profile. [Report Updated: 20072017] Prices from USD $250

SummaryAtara Biotherapeutics Inc Atara is a clinical research company that develops immunotherapies for cancers, autoimmune and severe viral infectious diseases. The company offers clinical stage Tcell product candidates such as ATA129, for the treatment of rituximabrefractory epsteinbarr virus associated posttransplant lymphoproliferative disorder after hematopoietic cell transplant and solid org...

Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin®1 (bevacizumab)

Results demonstrate equivalence in objective response rate in patients with advanced non-squamous non-small cell lung cancer Pfizer Inc. (NYSE:PFE) today announced that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin® (bevacizumab), met its primary objective. PF-06439535 is being deve...

Renflexis, a biosimilar to Remicade, launched in the US

Renflexis, a biosimilar for Remicade that was approved by the FDA in April, has now been launched in the United States, according to a company press release.“Since we were established 5 years ago, we have strived to bring high-quality treatment options at a lower cost to U.S. patients,” Christopher Hansung Ko, president and chief executive officer of Samsung Bioepis, Co., Ltd., said in the rel...

Merck, Samsung Bioepis Launch Remicade Biosimilar in U.S.

Merck & Co. today said it has launched in the U.S. a biosimilar of Remicade ® (infliximab), the blockbuster immune-mediated inflammatory disorders treatment it markets outside the U.S., including Europe, while partner Janssen Biotech markets the drug stateside. The biosimilar, to be marketed as Renflexis™ (infliximab-abda), is the first to reach the U.S. market through a global bios...

Stealth BioTherapeutics Initiates Phase 2/3 Study of Elamipretide in Patients With Barth Syndrome

BOSTON, July 24, 2017 /PRNewswire/ -- Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced the initiation of TAZPOWER, a Phase 2/3 study evaluating elamipretide in patients with Barth syndrome. Barth syndrome is a rare genetic mitochondrial disease, caused by mutations in the TAZ gene, and cha...

Stealth Biotherapeutics Initiates Phase II/III Study of Elamipretide In Patients With Barth Syndrome

  Life Sciences Jobs   ...

Cancer Immunotherapy Company Vaxil BioTherapeutics Appoints As Chief Medical Officer

  Life Sciences Jobs   ...

Basal Cell Carcinoma Basal Cell Epithelioma Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250

DelveInsight's, Basal Cell Carcinoma Basal Cell Epithelioma Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Basal Cell Carcinoma Basal Cell Epithelioma. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Basal Cell Carcinoma Basal Cell Epithelioma. This report provides in...

Paragon Appoints Deborah Wild as VP Quality and Regulatory Affairs

BALTIMORE, July 20, 2017 /PRNewswire/ -- Paragon Bioservices, a global leader in the manufacturing of biopharmaceuticals and vaccines, announced today the appointment of Deborah Wild to the position of Vice President, Quality and Regulatory Affairs, where she will focus on accelerating our quality agenda. "We are building a world class team and Ms. Wild's experience and leadership is spo...

Today's Research Report Coverage on Biotech Stocks -- Rexahn Pharma, Protalix BioTherapeutics, Navidea Biopharma, and Biostage

NEW YORK, July 19, 2017 /PRNewswire/ -- If you want a Stock Review on RNN, PLX, NAVB, or BSTG then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Pre-market, DailyStockTracker.com scans Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN), Protalix BioTherapeutics Inc. (NYSE MKT: PLX), Navidea Biopharmaceuticals Inc (NYSE MKT: NAVB), and Biostage ...

Venous Leg Ulcers Pipeline Insight, 2017 [Report Updated: 10072017] Prices from USD $1250

DelveInsight's, Venous Leg Ulcers Pipeline Insights, 2017, report provides comprehensive insights about pipeline drugs across this Venous Leg Ulcers. The key objective of the report is to establish the understanding for all the pipeline drugs that are undergoing research across Venous Leg Ulcers. This report provides information on the therapeutic development for Venous Leg Ulcers, dealing with a...

Estonian co buys InSight Biopharmaceuticals

A court approved the sale of the company, which is in liquidation.

First U.S. Avastin and Herceptin Biosimilars

On Thursday, July 13, 2017, FDA's Oncological Drugs Advisory Committee unanimously recommended approval of biosimilars of two blockbuster cancer drugs. The first, Amgen and Allergan's ABP-215 , is a proposed biosimilar of Roche/Genentech's Avastin , a monoclonal antibody used in the treatment of a number of different cancers.

Agilent Technologies Presents Thought Leader Award to Dr. Ram Sasisekharan

Influential MIT Researcher Recognized for Advancing the Use of Analytical Techniques and Multilayer Analysis for Characterization of Biopharmaceuticals Agilent Technologies Inc. (NYSE: A) today announced that Ram Sasisekharan, Ph.D., has received an Agilent Thought Leader Award in recognition of his contributions in the field of biologics charac...

J&J: Remicade holding up better than expected

While second quarter sales slipped 14% for the anti-inflammatory drug, the big pharma noted that biosimilars played a muted role in that decline.

Cold Chain Technologies and the Parenteral Drug Association Team Up for a New Course Offering

FRANKLIN, Mass., July 17, 2017 /PRNewswire/ -- Cold Chain Technologies (CCT), the leading source for temperature-controlled packaging solutions for all segments of the life science supply chain and the Parenteral Drug Association (PDA), the leading global facilitator of science, technology and regulatory information are pleased to announce "Temperature Sensitive Packaging and Distribution for...

Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-A 20 Million Cell Cohort

FREMONT, Calif., July 17, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced completion of enrollment and dosing of the AIS-A 20 million cell cohort in the company's ongoing SCiStar Phase 1/2a clinical study of AST-OPC1 in complete cervical spinal cord injury (SCI). In this cohort, five pa...

FDA Panel Backs 2 Biosimilars, ALDR Abuzz, MDXG Q2 Revenue Grows 33%

Today's Daily Dose brings you news about Alder's stock offering; FDA panel recommendation of 2 biosimilar candidates; Sangamo's investigational drugs SB-318 and SB-913 getting Fast Track designation; Pfizer's upcoming regulatory catalyst related to its rheumatoid arthritis drug; Mallinckrodt's progress in its CONFIRM trial and MiMedx Group's better-than-expected Q2 revenue.

Mylan Explores the Patient-Centric Road to Biosimilars

Iselin, NJ, July 14, 2017 --(PR.com)-- SMi Group has announced that Mr Chrys Kokino, Head Biologics Commercial at Mylan has joined the speaker line-up for the 4th annual Biosimilars North America conference in New Jersey. Chrys will present a talk entitled "The Road to Biosimilars: Reaching our destination with the patient in mind." This session, focusing on biosimilar usability and ef...

Celltrion Inc 068270 Financial and Strategic SWOT Analysis Review [Report Updated: 05072017] Prices from USD $125

Celltrion Inc 068270 Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your ...

Axial Biotherapeutics Makes Inaugural Appointments to its Scientific and Clinical Advisory Board

Axial Biotherapeutics, a biotechnology company building a unique class of microbial-targeted therapeutics for neurological diseases, today announced the appointment of leading experts in the field of Autism Spectrum Disorders (ASD) to its newly formed scientific and clinical advisory board (SAB). The recently appointed board will serve as a strategic resou...

Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-B 10 Million Cell Cohort

FREMONT, Calif., July 12, 2017 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced completion of enrollment and dosing of the AIS-B 10 million cell cohort in the company's ongoing SCiStar Phase 1/2a clinical study of AST-OPC1 in complete cervical spinal cord injury (SCI). In this cohort, five pa...

Innovate Biopharmaceuticals Submits Orphan Drug Application To FDA For Pediatric Ulcerative Colitis Indication

  Life Sciences Jobs   ...

Quick Search
Advertisement
 

review and buy Biotechnology Products market research data and corporate reports here